Where it is registered
Each register with its number of medicines and a few of them.
United States
FDA · 7 medicines
- Cutaquig2G/12ML · Solution · Octapharma Pharmazeutika Produktionsges.m.b.H.
- Cutaquig1.65G/10 ML · Solution · Octapharma Pharmazeutika Produktionsges.m.b.H.
- Cutaquig8G/48ML · Solution · Octapharma Pharmazeutika Produktionsges.m.b.H.
- Cutaquig3.3G/20 ML · Solution · Octapharma Pharmazeutika Produktionsges.m.b.H.
All medicines with Immune globulin subcutaneous
Every register, a page at a time. Strengths and packs are on each medicine’s page.
24 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Cutaquig | United States | 1G/6ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Cutaquig | United States | 8G/48ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Cutaquig | United States | 3.3G/20 ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Cutaquig | United States | 1.65G/10 ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Cutaquig | United States | 2G/12ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Cutaquig | United States | 4G/24ML | Solution | Marketed | Octapharma Pharmazeutika Produktionsges.m.b.H. |
| Vivaglobin | United States | 160MG/ML | For Injection | Withdrawn | CSL Behring GmbH |
| Cuvitru | United States | 10G/50ML | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Cuvitru | United States | 8G/40ML | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Cuvitru | United States | 4G/20ML | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Cuvitru | United States | 1G/5ML | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Cuvitru | United States | 2G/10ML | Injection | Marketed | Takeda Pharmaceuticals U.S.A., Inc. |
| Hizentra | United States | 1G/5ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 4G/20ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 2G/10ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 10G/50ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 10G/50ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 4G/20ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 2G/10ML | Injection | Marketed | CSL Behring AG |
| Hizentra | United States | 1G/5ML | Injection | Marketed | CSL Behring AG |
| Xembify | United States | 1GM MG/ML | Injection | Marketed | Grifols Therapeutics LLC |
| Xembify | United States | 2GM MG/ML | Injection | Marketed | Grifols Therapeutics LLC |
| Xembify | United States | 10GM MG/ML | Injection | Marketed | Grifols Therapeutics LLC |
| Xembify | United States | 4GM MG/ML | Injection | Marketed | Grifols Therapeutics LLC |
Brand names
The same brand on several registers.
Companies
The companies holding its medicines, the most first.
Sources
Compiled by Prognia from the public medicine registers of FDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.
At a glance
- Registers
- 1
- Medicines
- 7
- Companies
- 2